Imagion Biosystems (ASX:IBX): IND is secured and Phase 2 is good to go!
Imagion Biosystems just removed the final procedural barrier to initiating its planned Phase 2 clinical study for MagSense in HER2+ breast cancer. The company has secured IND clearance from the FDA in an achievement that is the company’s most important to date from a regulatory perspective and is an endorsement of its efforts. MagSense promises […]